Cargando…
The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) frequently presents as advanced stage with poor prognosis and high mortality. Systemic treatment is the treatment of choice for advanced disease. In 2007, the first multi-kinase inhibitor (MKI) sorafenib was approved and shown to modestly prolong overall survival (OS)....
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Liver Cancer Association
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565543/ https://www.ncbi.nlm.nih.gov/pubmed/37589044 http://dx.doi.org/10.17998/jlc.2023.07.17 |